EKSO Quote, Financials, Valuation and Earnings

Picard Medical has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of --. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat Picard Medical's return on equity of --.

Ekso Bionics Holdings, Inc. has a consensus price target of $7.75, signalling upside risk potential of 59.47%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Ekso Bionics Holdings, Inc. has higher upside potential than Picard Medical, analysts believe Ekso Bionics Holdings, Inc. is more attractive than Picard Medical.

Ekso Bionics Holdings, Inc. has a beta of 0.817, which suggesting that the stock is 18.349% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are larger than Picard Medical quarterly revenues of --. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is higher than Picard Medical's net income of --. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 4.52x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of -862.39%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat VolitionRX Ltd.'s return on equity of --.

Ekso Bionics Holdings, Inc. has a consensus price target of $7.75, signalling upside risk potential of 59.47%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 759.38%. Given that VolitionRX Ltd. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.817, which suggesting that the stock is 18.349% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 4.52x versus 17.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of -1037.17%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Ekso Bionics Holdings, Inc. has a consensus price target of $7.75, signalling upside risk potential of 59.47%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1819.25%. Given that Catheter Precision, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.817, which suggesting that the stock is 18.349% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 4.52x versus 9.31x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -33.62% compared to Ekso Bionics Holdings, Inc.'s net margin of 3.93%. Ekso Bionics Holdings, Inc.'s return on equity of -85.7% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Ekso Bionics Holdings, Inc. has a consensus price target of $7.75, signalling upside risk potential of 59.47%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Ekso Bionics Holdings, Inc..

Ekso Bionics Holdings, Inc. has a beta of 0.817, which suggesting that the stock is 18.349% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Ekso Bionics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ekso Bionics Holdings, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Ekso Bionics Holdings, Inc. quarterly revenues are $4.2M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Ekso Bionics Holdings, Inc.'s net income of -$1.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Ekso Bionics Holdings, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ekso Bionics Holdings, Inc. is 4.52x versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.